Comprehensive Proteomic Analysis of Influenza Virus Polymerase Complex Reveals a Novel Association with Mitochondrial Proteins and RNA Polymerase Accessory Factors

Birgit G. Bradel-Tretheway,1‡§ Jonelle L. Mattiacio,2‡ Alexei Krasnoselsky,1 Catherine Stevenson,2 David Purdy,1 Stephen Dewhurst,2¶ and Michael G. Katze1,3*¶

Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington 98195; Department of Microbiology and Immunology, University of Rochester, Medical Center, Rochester, New York 14642; and Washington National Primate Research Center, University of Washington, Seattle, Washington

Received 10 March 2011/Accepted 8 June 2011

The trimeric RNA polymerase complex (3P, for PA-PB1-PB2) of influenza A virus (IAV) is an important viral determinant of pathogenicity and host range restriction. Specific interactions of the polymerase complex with host proteins may be determining factors in both of these characteristics and play important roles in the viral life cycle. To investigate this question, we performed a comprehensive proteomic analysis of human host proteins associated with the polymerase of the well-characterized H5N1 Vietnam/1203/04 isolate. We identified over 400 proteins by liquid chromatography-tandem mass spectrometry (LC-MS/MS), of which over 300 were found to bind to the PA subunit alone. The most intriguing and novel finding was the large number of mitochondrial proteins (~20%) that associated with the PA subunit. These proteins mediate molecular transport across the mitochondrial membrane or regulate membrane potential and may in concert with the identified mitochondrial-associated apoptosis inducing factor (AIFM1) have roles in the induction of apoptosis upon association with PA. Additionally, we identified host factors that associated with the PA-PB1 (68 proteins) and/or the 3P complex (34 proteins) including proteins that have roles in innate antiviral signaling (e.g., ZAPS or HaxI) or are cellular RNA polymerase accessory factors (e.g., polymerase I transcript release factor [PTRF] or Supt5H). IAV strain-specific host factor binding to the polymerase was not observed in our analysis. Overall, this study has shed light into the complex contributions of the IAV polymerase to host cell pathogenicity and allows for direct investigations into the biological significance of these newly described interactions.
induction of apoptosis during influenza virus infection (9, 14, 21, 46, 69). PB2 has also been found to interact with IPS-1 at the mitochondria, where it may be involved in controlling virus-induced apoptosis as well as regulating innate antiviral immune responses (21, 29). Together, these findings suggest an important role for the mitochondria in the influenza virus life cycle. We were interested in determining whether PA may have similar functions as PB1-F2 or PB2 that may help understand the underlying mechanism that contributes to virulence.

Another interest was to identify factors that bind to only the heterotrimeric form of the polymerase complex since only a few 3P-binding partners have been described. Thus far, it is known that the 3P complex interacts with the large subunit of the cellular RNA polymerase II (Pol II) (12, 63). It is thought that the scavenging of RNA Pol II by the 3P complex serves multiple purposes in the influenza virus life cycle, such as the induction of premature termination of RNA polymerase II transcription, which ultimately leads to host protein synthesis shutoff and may help the 3P complex to gain access to polymerase accessory factors such as capped mRNA fragments and splicing factors (12, 63).

We utilized a comprehensive approach to identify the cellular factors that bind to the influenza virus polymerase complex or its subunits. In this approach, we purified the H5N1 (Vietnam/1203/04 [VN/1203]) polymerase (3P) complex and its subunit components (PA and PA-PB1) from human lung epithelial cells (A549 cell line) infected with adenovirus (Ad) vectors encoding these proteins. This novel expression system allows for the expression and purification of high levels of polymerase proteins (2). We analyzed proteins in the purified fractions by mass spectrometry, either before or after nuclease treatment to remove copurified RNA (and to dissociate protein complexes held together through an RNA intermediate). Using a subtractive analysis, we were able to identify host factors that bind to PA, PA-PB1, or the 3P complex. It has to be stressed that factors identified to bind, to PA or PA-PB1 may ultimately also bind to PA-PB1, or the 3P complex. It has to be stressed that factors identified to bind, e.g., to PA or PA-PB1 may ultimately also bind to PA-PB1, or the 3P complex. In this approach, we purified the

**Influenza virus polymerase purification.** Briefly, A549 cells were infected with adenovirus vectors encoding influenza virus polymerase proteins either alone (PA-TAP) or in combination with PB1 (PA-PB1), PB2 (PA-PB2), or PB1 and PB2 (3P complex); uninfected A549 cells were used as a control. Cell lysates were prepared 48 h postinfection (hpi) and left untreated or treated with RNase A (100 μg/ml) and DNase I (50 μg/ml) on ice for 30 min prior to purification by affinity chromatography using IgG-Sepharose beads, as described previously (2). Total cell lysates were either left untreated or treated, prior to IgG affinity purification. Successful nuclease treatment of the lysates was verified by agarose gel electrophoresis and ethidium bromide staining (data not shown). Elution fractions were pooled and concentrated in 100 mM NH4HCO3 using Amicon Ultra (3,000-molecular-weight cutoff [MWCO]) centrifugation devices. Concentrated fractions contained approximately 1 to 2 μg of total protein per μl.

**Vector construction for host factor coimmunoprecipitations (co-IPs).** The pShCMV-based expression vectors encoding PA, PB1, and PB2 were constructed as described previously (2), except PA-VN/1203, which was cloned without a TAP tag, and PA-VN/1203, which was cloned with a His6 tag only. To obtain host factor expression plasmids for Flag-tagged proteins, the coding regions of Sup35H (NM_0011111020), P(RM (NM_012322), and AIFM1 (NM_004208) were PCR amplified from cDNA. The cDNA of Sup35H or P(RM was cloned into the XhoI and BglII sites of the expression vector pCAGGS-NH2 Flag, and AIFM1 was cloned into EcoRI and SalI sites of expression vector pCAGGS-COOH Flag. The pCAGGS Flag vectors were kindly provided by Luis Martinez-Sobrido (University of Rochester, Rochester, NY).

**Antibodies and coimmunoprecipitations.** To analyze binding of transiently expressed proteins, expression plasmids (indicated in the relevant figure legends) were transfected into HEK293T cells (~90% confluence, 12-well plate) using Lipofectamine 2000 (Invitrogen). At approximately 24 h posttransfection, cells were washed with phosphate-buffered saline (PBS) and lysed in 200 μl of radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride [PMSF], 1 mM sodium orthovanadate, 1 mM sodium fluoride) supplemented with complete protease inhibitor (Complete Mini; Roche). Cellular debris was pelleted by centrifugation, and whole-cell lysate supernatant was incubated with 1 μg of anti-Flag antibody (Sigma-Aldrich) overnight, followed by rotation at 4°C, 20 μl of protein G agarose beads (Roche) overnight, and beads were washed three times with wash buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% NP-40, and protease inhibitor mix). Bound proteins were eluted by boiling for 5 min with 1× SDS-polyacrylamide gel loading buffer (50 mM Tris-HCl [pH 6.8], 2% SDS, 10% glycerol, 100 mM dithiothreitol [DTT], 0.01% bromophenol blue).

For co-IP of proteins from cells infected with influenza virus, a confluent well of A549 cells (~106 cell equivalent) in a six-well plate was infected with influenza A/WSN/33 virus (MOI of 10). The cells were collected at various times postinfection (24, 30, and 42 h), washed with PBS, and lysed in 500 μl of RIPA lysis buffer (supplemented as described above). Lysates were cleared of cellular debris by centrifugation for 5 min at 4°C (13,000 rpm). A total of 200 μl of the cleared lysate was transferred into a new tube and subjected to immunoprecipitation using 1 μg of anti-H1N1 PA rabbit polyclonal antibody. After a 1-h rotation at 4°C, 20 μl of protein A agarose beads (Santa Cruz) was mixed with the antibody-antigen complexes and rotated overnight. Beads were recovered by centrifugation at 2,500 rpm for 5 min and washed three times with wash buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 0.1% NP-40, 1 mM PMSF) and then resuspended in 1× SDS sample buffer. Bound proteins were eluted by boiling for 5 min and separated by electrophoresis through a 7.5% polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane and analyzed by Western blotting using PA- and AIFM1-specific antibodies. Proteins were visualized with an enhanced chemiluminescence (ECL) detection kit (Amersham Life Science).

The WSN virus (A/WSN/33), a generous gift from T. Takimoto (University of Rochester), was grown in MDCK cells at 33°C for 72 h in DMEM supplemented with 10% fetal bovine serum (FBS), 50 IU of penicillin ml−1, 50 μg of streptomycin ml−1, and 2 mM glutamine. The polymerase genes of the H1N1 (A/WSN/33) and H5N1 (A/Vietnam/1203/04) viruses were assembled as described previously (2). The polymerase genes from the H1N1 virus of a recent pandemic (CA/04/09) were human codon optimized and assembled from synthetic oligonucleotides by EpOichiplabs (Missouri City, TX); protein identifiers (IDs) for polymerase genes of CA/04 were ACP41456.1, ACP4130.1, and ACP4131.2. The adenoviral vectors were constructed as described previously (2). Briefly, PA from each viral strain was tagged at the C terminus with a tandem affinity purification (TAP) tag, and the viral polymerase genes were cloned into adenoviral expression vectors as described for A/Vietnam/1203/04. All adenovirus infections were performed at a multiplicity of infection (MOI) of 1,000, except for recombinant Ad type 5 expressing the VN/1203 PA (rAd5-PA-VN/1203), where an MOI of 100 was used (2).

**Cell lines and viruses.** Human lung epithelial cells (A549) and HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS). 50 IU of penicillin ml−1, 50 μg of streptomycin ml−1, and 2 mM glutamine. The polymerase genes of the H1N1 (A/WSN/33) and H5N1 (A/Vietnam/1203/04) viruses were assembled as described previously (2). The polymerase genes from the H1N1 virus of a recent pandemic (CA/04/09) were human codon optimized and assembled from synthetic oligonucleotides by EpOichiplabs (Missouri City, TX); protein identifiers (IDs) for polymerase genes of CA/04 were ACP41456.1, ACP4130.1, and ACP4131.2. The adenoviral vectors were constructed as described previously (2). Briefly, PA from each viral strain was tagged at the C terminus with a tandem affinity purification (TAP) tag, and the viral polymerase genes were cloned into adenoviral expression vectors as described for A/Vietnam/1203/04. All adenovirus infections were performed at a multiplicity of infection (MOI) of 1,000, except for recombinant Ad type 5 expressing the VN/1203 PA (rAd5-PA-VN/1203), where an MOI of 100 was used (2).
Rochester, Rochester, NY), was propagated in MDCK cells as described previ-
ously (5).

Antibodies were obtained from the following sources: anti-H1N1 PA rabbit
polycanal antibody (ABIN398898) was purchased from Antibodies-Online
GmbH (Atlanta, GA); PB1-specific (VK-20), PB2-specific (VN-19), and anti-goat
IgG horseradish peroxidase (HRP)-conjugated (Sc-2033) specific antibodies
were obtained from Santa Cruz; ECL anti-rabbit IgG-HRP (NA934V) and ECL
anti-mouse IgG-HRP (NA931V) were purchased from Amersham, and anti-
Penta-His (mouse) was from Qiagen. The following antibodies to detect specific
cellular host factors were obtained from Santa Cruz: goat polyclonal antibodies
directed against AIFM1 (sc-9416), IPO5 (sc-11369), and IPO7 (sc-55230) and
a mouse monoclonal directed against PRKDC (protein kinase, DNA-activat-
catalytic subunit; sc-5690).

Mass spectrometry. Samples were prepared with PPS Silent Surfactant (Pro-
tein Discovery, Inc., Knoxville, TN) based on the manufacturer's recommended
protocol and digested with trypsin (treated with sequencing-grade trypsin/phenylalanyl chloromethyl ketone (TPCK); Promega). Briefly, trypsin digestion
was carried out in 50 mM ammonium bicarbonate buffer, pH 7.8, overnight at
37°C at a trypsin to protein ratio of 1:50. The peptides were analyzed on an
LTQ-Orbitrap mass spectrometer (Thermo Scientific). The reverse-phase column
consisted of a trap column (100 μm by 1.5 cm) of Magic C18AQ resin in an
IntegraFrit (New Objective) connected in-line to an analytical column (75 μm
by 27 cm) of Magic C18AQ resin in a PicoFrit. The liquid chromatography-tandem
MS (LC-MS/MS) acquisition consisted of a full mass spectrum followed by up to
five data-dependent MS/MS spectra of the five most abundant ions. The full mass
spectra scan range was 400 to 1,800 m/z, and the instrument resolution was set
to 60,000. The data-dependent scans were collected using the following settings:
repeat count of 1, repeat duration of 30, exclusion list size of 100, exclusion
duration of 45, and exclusion mass width of 0.5 m/z low and 1.5 m/z high.
Charge state screening was used allowing analysis of +2, +3, and +4 and higher
charge states while rejecting analysis of +1 and unassigned charge states. Each
sample was analyzed in three technical replicates (unless otherwise indicated)
of the total 1 to 2 g of protein. The LC-MS/MS data were searched against the
human International Protein Index (IPI) database (version 3.70) appended with
the total 1 g of protein. The data processing and database search were
performed in X!Tandem search engine. Peptide Prophet (34) was used to evaluate
peptide assignment at a false-discovery rate (FDR) of <5%, and Protein Prophet (47) was used to group peptides into proteins. Only peptides
that passed the 5% FDR threshold for Peptide Prophet were used for the
grouping. Contaminant proteins (evident from intermittent blank runs) were
removed from further analysis.

We also allowed for up to 10% of carryover in the negative-control lysate; this
decided that we did not erroneously filter out more abundant peptides that
were observed at much smaller amounts in the control lysate. In addition, only pro-
teins with multiple peptide occurrences (across all conditions) were analyzed
further. The protein occurrence among polymerase fragments was analyzed on the
Entrez Gene level, using the Venn diagram tool provided in the Resolver soft-
ware (Rosetta). Functional enrichment analysis was performed in DAVID (Da-
verse, version 6.7, and Ingenuity Pathway analysis (IPA). Protein interac-
tion networks were extracted from the human proteome database present in the
Ingenuity Pathway Knowledge Base (IPKB). The P values for each canonical
pathway were calculated with a right-tailed Fisher's exact test, which compares
the number of proteins that participate in a given pathway to the total number
of proteins that were infected with adenoviruses expressing either PA
(PA-TAP, PA and PB1 (PA-PB1), or PA, PB1, and PB2 (3P complex); uninfected A549 cells were used as a control. Affi-
nity purification was directed against the TAP tag; therefore,
only polymerase proteins that associated with PA were precipi-
tated by this method (Fig. 1A). Affinity-purified complexes precipitated from two sets of independently generated cell
lysates, described as set 1 and set 2, were analyzed by liquid
chromatography-mass spectrometry (LC-MS). Set 1 consisted
of polymerase components from the VN/1203 strain (PA, PA-
PB1, and 3P) that were either treated with nuclease or left
untreated. Samples from set 2 consisted of an independent repeat experiment of untreated polymerase components
of the VN/1203 strain as well as 3P complexes from the WSN
and CA/04 strains (Fig. 1A).

Affinity-purified proteins were prepared as described previ-
ously (2) and separated by polyacrylamide gel electrophoresis (PAGE), and purified proteins were detected by silver staining (Fig. 1B). All viral polymerase proteins were detected, as
indicated in Fig. 1B, along with other unidentified cellular pro-
teins. The viral polymerase proteins were also verified by West-
ern blot analysis (data not shown) and resulted in one single
protein band for each viral protein. In contrast to the purified
polymerase complexes, few cellular proteins were visible in the
negative-control sample from untreated A549 cells. No obvi-
ous differences in protein staining patterns were observed be-
 tween polymerase complexes purified from untreated versus
nuclease-treated cell lysates (data not shown).

In our approach, affinity-purified protein complexes from untreated or nuclease-treated cell lysates were then subjected

FIG. 1. Purification of the influenza virus polymerase complex and subunit components from A549 cells. (A) Overview of the influenza virus polymerase purification and expression technique. A549 human lung epithelial cells were infected with adenoviruses (rAd5) expressing the indicated proteins (PA-TAP, PA, and PB2). Control A549 cell lysates or A549 cell lysates expressing PA, PA-PB1, or the 3P complex from VN/1203 (H5N1), WSN (H1N1), or CA/04 (H1N1) were left untreated (−) or treated (+) with nuclease (DNase and RNAsese A). The polymerase complex (PA-TAP/PB1/PB2) or the subunit compo-
nents (PA-TAP, PA-TAP/PB1, and PA-TAP/PB2) were purified by
IgG affinity chromatography and elution with tobacco etch virus proteinase.
(B) A549 cells were transduced with adenovirus vectors, encod-
ing the indicated VN/1203 polymerase subunits (top). After 48 h, cell
lysates were prepared and subjected to IgG affinity chromatography
and elution with tobacco etch virus proteinase. Nuclease-treated, affi-
nity-purified polymerase subunits were then electrophoretically sepa-
rated on a 7.5% polyacrylamide gel and detected by silver staining. The
polymerase subunits (PB1, PA, and PB2) are indicated, as are the
positions of molecular mass markers (left). There were no obvious
differences in banding patterns compared to samples not treated
with nuclease (data not shown).
protein complexes held together mainly through an RNA intermediate versus those held together by direct protein-protein binding. Table 1 describes the underlying quality control (QC) matrix for the VN/1203 polymerase components (set 1), showing the relative abundance of viral proteins across the experimental conditions. A reasonable sequence coverage for each viral protein was achieved (60 to 74%), with 40 to 55 unique peptides detected for each viral protein (Table 1). The abundance of each viral protein was measured by the total number of spectral counts that match peptides to this particular viral protein (Table 1). All viral proteins were readily detected in samples from both experimental sets (see Table S1 in the supplemental material for the complete QC matrix on set 2). As expected, PB2 was detected only in the purified 3P complex while PB1 was detected only in the purified PA-PB1 and 3P complexes; PA was found in all purified complexes (also, as expected) (Table 1).

To identify nonspecific protein interactions with IgG-Sepharose beads as well as potential carryover during the LC-MS analysis (28), we included control cell lysates in our analysis. From all proteins identified by LC-MS (see master tables for each set in Table S2 in the supplemental material), we filtered out the nonspecific binders first, which were defined as proteins that were present in the purified viral polymerase fractions as well as the control lysate. A background list with the nonspecific binders was established, which included proteins such as tubulin, actin, keratin, EEF1, and serum albumin (see Table S2). To further increase confidence in protein assignments, only proteins for which multiple peptides were detected (across all conditions) were included in the list of polymerase binding partners. With this method, we detected a total of 509 proteins in set 1 and 743 proteins in set 2 as PA-, PA-PB1-, or 3P-binding partners. The union of these two data sets yielded 859 unique cellular host factors that were associated with the VN/1203 polymerase or subcomponents thereof.

Identification of VN/1203 PA-binding partners. Of the 859 cellular factors, 651 were found to bind to PA (Fig. 2). We identified 390 proteins in set 1 that bound to PA in untreated and nuclease-treated samples combined. Of these, 373 proteins bound to PA in the absence of nuclease treatment, and 207 proteins bound to PA after nuclease treatment (Fig. 2, PA -N and PA +N, respectively). Another 576 PA-interacting proteins were identified in set 2 (Fig. 2). All three protein groups overlapped by 166 proteins which we considered to represent proteins that bound to PA both in the presence and absence of any associated RNA (termed here “shared” factors).

Overall, the shared PA-binding proteins constituted more than 80% of the total complement of proteins identified in the nuclease-treated PA complex (207 total proteins) (Fig. 2, PA +N). In addition, we identified 140 proteins that appeared to bind to PA in an RNA-dependent fashion (Fig. 2) and were present in the PA fractions from both experimental sets. The top five canonical pathways associated with the 166 shared RNA-independent and the 140 RNA-dependent PA-binding partners, as well as both data sets combined (306 proteins), were determined by Ingenuity Pathway Analysis and are listed in Table 2. The number of molecules detected in each particular pathway is indicated together with their P values, calculated using a Benjamini-Hochberg multiple testing corrections. Pathways such as Ran signaling and caveolar-mediated endocytosis signaling have been described before, albeit not with regard to PA alone. Interesting and novel was the enrichment for proteins involved in mitochondrial properties such as mitochondrial dysfunction or oxidative phosphorylation. The association of PA with these proteins occurred mainly in the presence of nucleic acid (the RNA-dependent 140 proteins).

![FIG. 2. Cellular PA-binding partners. Venn diagram, representing 651 cellular proteins identified in affinity-purified complexes with PA in the absence of nuclease treatment (-N, Set 1; Set 2) and after nuclease treatment (+N, Set 1). We attribute the identification of more proteins in set 2 than in set 1 to slight differences in sample preparation between experiments. Numbers in the various boxes/sectors denote numbers of unique cellular proteins identified in each category. Highlighted in the center of this figure are the 166 cellular proteins that we defined as shared RNA-independent PA-binding partners (i.e., proteins which bound to PA both in the presence and absence of PA-associated nucleic acid). Highlighted in the top center of this figure are the 140 cellular proteins that we defined as RNA-dependent binding partners (i.e., proteins which bound to PA only when PA was also complexed with nucleic acid). All proteins derived from set 2 were not treated with nuclease.](http://jvi.asm.org/)

TABLE 1. MS data of the H5N1 influenza A virus polymerase complex (set 1)

<table>
<thead>
<tr>
<th>gi no.a</th>
<th>Protein nameb</th>
<th>Sequence coverage (%)</th>
<th>No. of unique peptides</th>
</tr>
</thead>
<tbody>
<tr>
<td>50313055</td>
<td>PA</td>
<td>74.47</td>
<td>55</td>
</tr>
<tr>
<td>50296440</td>
<td>PB1</td>
<td>60.11</td>
<td>40</td>
</tr>
<tr>
<td>50296548</td>
<td>PB2</td>
<td>66.14</td>
<td>43</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No. of spectral counts of the indicated proteinc</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA</td>
</tr>
<tr>
<td>PA</td>
</tr>
<tr>
<td>Without nuclease</td>
</tr>
<tr>
<td>1,102</td>
</tr>
<tr>
<td>With nuclease</td>
</tr>
<tr>
<td>1d</td>
</tr>
</tbody>
</table>

a NCBI gi number (sequence record identifier).
b From influenza virus A/Vietnam/1203/2004 (H5N1).
c Counts for each protein were averaged across technical replicates. PA-PB1 contains PA and PB1; 3P contains PA, PB1, and PB2.
d The nonzero values are most likely due to a slight carryover in subsequent LC-MS runs.
and remained the most significant pathway when both RNA-dependent and -independent factors were combined.

Next, we focused on the 166 shared RNA-independent PA-binding partners since these proteins were present in all three purified sample preparations (Fig. 2, PA set 1 with and without nuclease treatment and set 2) and are therefore likely to be true PA-binding partners. Figure 3 shows the main PA interaction network for the 166 cellular proteins with the major canonical pathways that were identified under Table 2. Interestingly, besides the Ran signaling, the aminoacyl-tRNA synthesis and the caveolar-mediated endocytosis pathways, we identified epidermal growth factor receptor (EGFR) as one of the major connecting points between these pathways (Fig. 3). Indeed, EGFR is also part of the caveolar-mediated endocytosis pathway and has recently been speculated to be important for influenza virus endocytosis (11). Also highlighted are those molecules (Fig. 3, orange symbols) that are involved in molecular transport such as protein and RNA transport. Overall, the findings summarized in Fig. 3 (see Table S3 in the supplemental material for a complete list of the 166 proteins) and Table 2 are broadly consistent with previous reports on biological pathways and host factors required for the influenza virus infectious cycle (31, 35). Additional information on each reported molecule such as amino acid coverage, peptide composition, and the relative abundance as measured by spectral counts can be found in the supplemental data (see Table S2).

Next, we used DAVID Bioinformatics resources to perform a functional enrichment analysis that condenses two identified gene lists (166 RNA-dependent genes and the combined gene list of 306 genes) into functional groups across the Gene Ontology (GO) categories (26). Table 3 shows the biological processes and the molecular functions in which these 166 shared factors (RNA independent) are involved. The main cellular components with which these proteins associated were the nuclear pore/envelope, the COPI vesicle coat, the mitochondrial, and endoplasmic reticulum (ER). The counts of the molecules associated with these cellular structures are shown in Table 3 along with their calculated P values (defined by DAVID Bioinformatics). These cellular structures have been previously reported to be important in the influenza virus life cycle; however, their role in the context of PA-binding proteins has not been defined. Of particular interest is the novel association of PA with mitochondrial proteins since only PB2 and PB1-F2 have been linked to mitochondria in the past (6, 9). In fact, the mitochondrion category even gained significance when the combined list of molecules from RNA-dependent and -independent factors (306 factors) were examined, suggesting that some functions of PA at the site of the mitochondria are RNA dependent.

From the 166 shared factors, we identified 33 PA-binding factors that located to mitochondria (P = 2.3E−06) (Table 3). Next, we compiled a heat map of these 33 factors across both experimental data sets which represents their relative abundance as measured by the average of individual spectral counts detected by LC-MS (Fig. 4). Most of the mitochondrial proteins identified were from the inner mitochondrial membrane and are involved in transmembrane transport. AIFM1 (apoptosis inducing factor, mitochondrial), one of the PA-associated mitochondrial proteins located at the inner mitochondrial membrane, was also one of the most readily detected PA-interacting partners, as measured by LC-MS.

Next to AIFM1, other readily detected, nonmitochondrial proteins were PRKDC (protein kinase, DNA activated) as well as the beta-importin IPO7. The relative abundance of these factors together with IPO5 (RanBP5), a previously identified binding partner of PA-PB1 (10), is shown in Fig. 5A in the form of a heat map. IPO5 is omitted from the complete list of PA- and PA-PB1-binding partners (see Table S3 in the supplemental material) because of the stringent exclusion criteria that were applied in analyzing our data. However, the heat map (Fig. 5A) clearly shows that IPO5 associates chiefly with the PA-PB1 dimer, which is in accordance with published data (10). We verified the binding of these four cellular host factors to H5N1 PA by Western blot analysis of affinity-purified complexes of polymerase or polymerase subcomponents (Fig. 5B). AIFM1, IPO5, and, to a somewhat lesser extent, IPO7 were detected in complex with PA alone as well as in the PA-PB1 and 3P-containing complexes (which also contain PA). Both IPO5 and IPO7 predominantly bound to PA-PB1 (Fig. 5B), which is consistent with our LC-MS results (Fig. 5A).

The LC-MS results (Fig. 5A) also suggested that these host cell factors interacted with the viral polymerase components in a strain-independent fashion since they were also detected in affinity-purified 3P complexes from the H1N1 strains WSN and CA/04. These results were further confirmed by Western blotting (Fig. 5C) where IPO5, IPO7, AIFM1, and PRKDC were detected in 3P complexes from all three of the viral strains tested (Fig. 5C).

We next focused our attention on AIFM1 since the interaction of PA with mitochondrial proteins has not been described before. We tested whether AIFM1, one of the most readily

<table>
<thead>
<tr>
<th>Protein group (n)</th>
<th>Canonical pathway</th>
<th>No. of molecules detected</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-independent</td>
<td>Ran signaling</td>
<td>5</td>
<td>8.76E−05</td>
</tr>
<tr>
<td>proteins (166)</td>
<td>Fatty acid biosynthesis</td>
<td>4</td>
<td>5.27E−04</td>
</tr>
<tr>
<td></td>
<td>Mitochondrial-mediated endocytosis signaling</td>
<td>4</td>
<td>6.00E−04</td>
</tr>
<tr>
<td></td>
<td>Aminoacyl-tRNA biosynthesis</td>
<td>4</td>
<td>4.31E−02</td>
</tr>
<tr>
<td></td>
<td>Purine metabolism</td>
<td>10</td>
<td>4.56E−02</td>
</tr>
<tr>
<td>RNA-dependent</td>
<td>Oxidative phosphorylation</td>
<td>10</td>
<td>1.04E−04</td>
</tr>
<tr>
<td>proteins (140)</td>
<td>Mitochondrial dysfunction</td>
<td>8</td>
<td>1.11E−03</td>
</tr>
<tr>
<td></td>
<td>Citrate cycle</td>
<td>4</td>
<td>5.86E−03</td>
</tr>
<tr>
<td></td>
<td>PXR/RXR activation</td>
<td>5</td>
<td>1.14E−02</td>
</tr>
<tr>
<td></td>
<td>Aminoacyl-tRNA biosynthesis</td>
<td>4</td>
<td>1.14E−02</td>
</tr>
<tr>
<td>Combined groups</td>
<td>Mitochondrial dysfunction</td>
<td>14</td>
<td>1.81E−05</td>
</tr>
<tr>
<td>(306)</td>
<td>Oxidative phosphorylation</td>
<td>15</td>
<td>1.81E−05</td>
</tr>
<tr>
<td></td>
<td>Aminoacyl-tRNA biosynthesis</td>
<td>8</td>
<td>6.64E−05</td>
</tr>
<tr>
<td></td>
<td>Ran signaling</td>
<td>5</td>
<td>4.94E−04</td>
</tr>
<tr>
<td></td>
<td>Caveolar-mediated endocytosis signaling</td>
<td>9</td>
<td>4.94E−04</td>
</tr>
</tbody>
</table>

\( a \), number of proteins.

\( b \), Ingenuity Pathway analysis category.

\( c \), As determined by Benjamini-Hochberg multiple testing correction.

\( d \), PXR, pregnane X receptor; RXR, retinoid X receptor.
detected mitochondrial proteins, could also be detected in a complex with PA by coimmunoprecipitation (co-IP) experiments. Since AIFM1 binding to the viral polymerase did not occur in a strain-specific fashion, we transfected 293T cells with vectors encoding polymerase proteins (PA, PB1, and PB2) from the WSN strain together with Flag-tagged AIFM1. Cells were harvested at 24 h posttransfection, and AIFM1 was immunoprecipitated with an anti-Flag antibody. The polymerase proteins and AIFM1 were readily detected in the total cell extract (Fig. 6, lower panel). AIFM1 efficiently coprecipitated PA when PA was either expressed alone (Fig. 6, lane 2, top panel) or together with PB1 and PB2 (Fig. 6, lane 4, top panel). As expected, no polymerase components were detected in the absence of AIFM1-Flag (Fig. 6, lanes 1 and 3). These data are consistent with the notion that AIFM1 binds chiefly to PA (Fig. 5A and B) and suggest that AIFM1 binding to PA also occurs when in a complex with PB1 and PB2 (3P).

We next tested whether AIFM1 could also be detected in a complex with PA in A549 cells that were infected with wild-type influenza virus. We infected A549 cells with A/WSN/33 (H1N1) virus and prepared cell lysates at various times postinfection (24, 30, and 42 hpi). We then performed a coimmunoprecipitation assay using anti-PA antibody. PA of the WSN virus and AIFM1 were readily detected in the total cell extract (Fig. 6B, top and middle of left panel). AIFM1 was also detected in the protein complex that was immunoprecipitated with the PA-specific antibody (Fig. 6B, middle of right panel) at all times postinfection (24, 30, and 42 hpi); it was not, however, detected in immunoprecipitated complexes from mock-infected cells. These findings confirm that the interaction between AIFM1 and PA also occurs in the context of a virally infected cell.

Identification of PA-PB1 binding partners. Having identified cellular proteins that interact with PA, we were interested in proteins that bind to larger subcomponents of the influenza virus polymerase. We turned our attention first to the PA-PB1 dimer and looked for proteins that bound to the PA-PB1 dimer but were not found in the PA fraction. Since the PA-PB1 fraction contains unbound monomeric PA (2), the PA-specific binding partners were subtracted, presumably leaving only the PA-PB1-interacting partners. To be conservative in this analysis, we also subtracted out all proteins that were detected in association with PA from a second, independent set of experiments (set 2). We identified a total of 68 proteins that were...
present in the PA-PB1 fraction (with or without nuclease-treated fractions combined) but not in the PA fraction (Fig. 7A). These proteins could be specific interactors with the PA-PB1 dimer or with PB1 (remaining bound to PB1 when it is in a complex with PA).

We then separated out proteins that were present in only the untreated fraction (Fig. 7, −N), in only the nuclease-treated fraction (Fig. 7, +N), or present in both. We identified 23 proteins that were present in both the untreated and nuclease-treated samples (Fig. 7, −/+N), 34 proteins that were present in only the untreated sample, and 11 proteins that were present in only the nuclease-treated samples. In the untreated (−N) fraction, we mainly detected proteins that are involved in translation (such as ribosomal proteins), protein folding, and transcriptional regulation (Fig. 7A). We further detected cell surface proteoglycans (GPC1 and SDCL1) which may have a potential role in influenza virus entry. However, the exact role of viral polymerase binding to these proteins remains uncertain. Another protein we detected was the CCCH-type zinc finger protein ZC3HAV1 (also called ZAP), an antiviral protein that was reported to protect cells from infection by retroviruses as well as certain alphaviruses and filoviruses (1, 19).

We detected four isoforms of the ZAP protein, including ZAPS (isoform 2) (see Table S2 in the supplemental material). ZAPS facilitates the interaction of RIG-I with IPS-1, leading to the induction of antiviral gene expression, such as interferon beta (IFN-β) (24). It has been previously shown that PB2 of the viral polymerase can bind to IPS-1 and inhibit IFN-β production (29). Our findings also indicate that PA-PB1 (and possibly also the 3P complex) may have important functions in regulating innate antiviral immune responses by binding to ZAPS.

In the combined (Fig. 7, −/+N) fraction, we detected some ribosomal proteins, chaperones, proteins involved in proteolysis (proteasomal proteins), and the RNA polymerase II (Pol II) and I (Pol I) transcription termination factor (TTF2). In the nuclease-treated (+N) fraction, we detected proteasomal proteins, protein kinases, and transcriptional regulators. Among the last were the Pol II subunit POLR2C and the Pol I transcript release factor PTRF. These transcriptional regulators may directly be involved in the modulation of influenza virus RNA polymerase function.

Identification of 3P-binding partners. After completing our analysis of cellular proteins that interact with the PA-PB1 heterodimer, we next proceeded to identify proteins that interact specifically with the complete heterotrimeric polymerase complex (3P), comprising PA-PB1-PB2 (Fig. 7B). We subtracted out proteins that bound to PA alone or to PA-PB1 alone under both conditions (with and without nuclease treatment) (Fig. 7B). This analysis revealed a total of 34 proteins that bound uniquely to the 3P complex and not to PA or PA-PB1. These proteins could be specific interactors with the trimeric polymerase complex or with PB2 (remaining bound to PB2 when it is in a complex with PA).

Ten proteins bound specifically to the 3P complex, regardless of nuclease treatment (Fig. 7B, −/+N). These included proteins that may have important roles in the shuttling of the 3P complex from the nucleus to the cytoplasm (alpha-importins KPNA3 and KPNA4 [importin α-4 and α-3, respectively]) or in COPI-mediated transport (SDPR [serum deprivation response]). The importance of alpha-importins in the influenza A virus life cycle has been recognized before and has been attributed mainly to enhancement of transcription and replication, mediated by binding to PB2 and the nucleoprotein (NP) (17, 18, 65). However, the association of these particular importins with specifically the 3P complex is novel and may point to a specific nucleo-cytoplasmic transport mechanism of the 3P complex compared to its subunit components. Further, we detected the recently identified cap-binding protein GEMIN5 (3) and the main subunit of the RNA polymerase II (POLR2A), a previously identified binding partner of the 3P complex (31), which again may be directly involved in modulating influenza virus RNA polymerase function.

Twelve cellular proteins bound specifically to the 3P complex but only if the complex was not treated with nuclease (Fig. 7B, −N). These included some ribosomal proteins, transcrip-

<table>
<thead>
<tr>
<th>GO term</th>
<th>DAVID functional annotation</th>
<th>Group of 166 proteins</th>
<th>Combined group of 306 proteins</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>No. of molecules</td>
<td>P value</td>
</tr>
<tr>
<td>Biological process</td>
<td>Intracellular transport</td>
<td>32</td>
<td>1.40E−09</td>
</tr>
<tr>
<td></td>
<td>Intracellular protein transport</td>
<td>20</td>
<td>2.20E−06</td>
</tr>
<tr>
<td></td>
<td>COPI coating of Golgi vesicle</td>
<td>6</td>
<td>4.00E−06</td>
</tr>
<tr>
<td></td>
<td>Nucleocytoplasmic transport</td>
<td>12</td>
<td>5.60E−05</td>
</tr>
<tr>
<td>Molecular function</td>
<td>Nucleotide binding</td>
<td>54</td>
<td>2.10E−07</td>
</tr>
<tr>
<td></td>
<td>Protein transporter activity</td>
<td>9</td>
<td>1.20E−04</td>
</tr>
<tr>
<td></td>
<td>ATPase activity</td>
<td>13</td>
<td>5.60E−03</td>
</tr>
<tr>
<td>Cellular component</td>
<td>Organelle envelope</td>
<td>35</td>
<td>3.60E−13</td>
</tr>
<tr>
<td></td>
<td>Pore complex</td>
<td>13</td>
<td>2.50E−08</td>
</tr>
<tr>
<td></td>
<td>COPI vesicle coat</td>
<td>6</td>
<td>1.70E−06</td>
</tr>
<tr>
<td>Mitochondrion</td>
<td>33</td>
<td>2.30E−06</td>
<td>66</td>
</tr>
<tr>
<td></td>
<td>Endoplasmic reticulum</td>
<td>27</td>
<td>1.30E−04</td>
</tr>
</tbody>
</table>

a RNA-independent factors.
b Union of RNA-dependent and RNA-independent factors (166 + 140 proteins).
c P values were determined by a Benjamini-Hochberg multiple testing correction.
d The mitochondrion category is highlighted as being of particular importance (see text).
tional activators, and the DNA topoisomerase. Finally, 12 factors bound specifically to the 3P complex but only when the complex was exposed to nuclease treatment (Fig. 7B, 45). In addition to the well-described influenza virus antiviral protein MxA (Mx1), we identified four transcriptional regulators that belong to the Pol II regulatory network (HIV Tat-specific factor [HTat-SF1], PAF1, PRMT5, and Supt5H). These factors may directly affect viral polymerase function at the level of transcription and/or replication.

Overall, these studies showed that one major interaction network among the cellular host factors identified in association with the PA-PB1 heterodimer and the full 3P polymerase complex is the RNA-polymerase II interaction network (Fig. 8A). We next selected two Pol II-interacting proteins (Supt5H and HTat-SF1) and one Pol I-interacting protein (PTRF) to be analyzed further. Supt5H and PTRF are cellular factors that have not been previously described to associate with the influenza virus polymerase; HTat-SF1 has been reported to bind only to the viral nucleoprotein and not to the polymerase itself (45). Figure 8b shows a heat map of the relative abundance of these proteins as identified by LC-MS. It can be readily appreciated from Fig. 8b that all three proteins mainly associate with the trimeric polymerase complex; however, in the case of PTRF some binding to PA-PB1 is observed as well.

We next confirmed the interaction of Supt5H and PTRF with the polymerase complex by reciprocal coimmunoprecipitation studies. We transfected Flag-tagged Supt5H and PTRF into HEK293T cells along with vectors encoding PA, PB1, and PB2. Cells were harvested at 24 h posttransfection, and total cell extracts were analyzed by immunoblotting for the presence of the Flag-tagged proteins by using antisera specific for IPO5, IPO7, and AIFM1 as well as anti-PA, anti-PB1, and anti-PB2. (C) A549 cells were transduced with adenovirus vectors encoding the indicated VN/1203 (H5N1) polymerase proteins (3P denotes the PA-PB1-PB2 complex). Non-nuclease-treated PA-containing protein complexes were then purified by affinity chromatography, along with a negative-control eluate (A549), as described in Fig. 1A. Protein content in these complexes was evaluated by Western blotting, using antisera specific for IPO5, IPO7, and AIFM1 as well as anti-PA, anti-PB1, and anti-PB2.
harvested at 24 h posttransfection, and total cell extracts were analyzed by immunoblotting for the presence of the Flag-tagged proteins by using an anti-Flag antibody as well as for the presence of individual polymerase proteins using PA-, PB1-, and PB2-specific antibodies (Fig. 9B, bottom panel). Viral proteins were detected in the control samples transfected with empty vector (lanes 1 to 3) and in samples transfected with the Flag-tagged Supt5H constructs (lanes 4 to 6). A coimmunoprecipitation assay was performed with an anti-Flag antibody to precipitate protein complexes containing Supt5H (Fig. 9B, top panel). Supt5H was detected in those samples that were transfected with the corresponding expression construct (lanes 4 to 6) but not in the empty vector control samples (lanes 1 to 3). Supt5H most efficiently coprecipitated the complete 3P complex (lane 6), but it also precipitated the PA-PB1 complex and, weakly, PA alone. Densitometry was performed to quantitate the ratio of PA to Supt5H in the immunoprecipitated fractions. The ratio of PA/Supt5H was set to 1 for the 3P fraction (Fig. 9B, lane 6) and compared with that of PA alone (lane 4) and PA with PB1 (lane 5). A smaller fraction of PA (0.39) was pulled down by Supt5H when it was expressed alone or together with PB1 (0.64), suggesting preferential binding of Supt5H to the 3P complex. Collectively, the results in Fig. 9 corroborate our LC-MS data and confirm that PTRF and Supt5H are, indeed, polymerase binding partners with the ability to interact with the 3P complex.

**DISCUSSION**

In this study, we conducted an unbiased proteomic approach to identify host cell factors that bind to the influenza virus polymerase; our goal was to provide a framework that will guide future studies in dissecting out the mechanism of influenza virus polymerase function. In our study, we put a particular focus on cellular factors that bind to PA, PA-PB1, and the full trimeric complex.

An important advantage of our analytical method was the very high sensitivity of the comprehensive LC-MS approach. As a result, we identified over 400 potential polymerase binding partners, some of which have been described previously to interact with influenza virus viral proteins and/or be important in the influenza virus life cycle (see Table S4 in the supplemental material). This large number of putative binding partners includes several proteins (62) that have been previously identified in genome-wide screens (see Table S4A) and are known to regulate viral replication. Some of these interactions affect viral replication by targeting influenza virus entry and hemagglutinin (HA) trafficking (COPI coat complex), by inducing the degradation of host cell proteins (proteasome complex), by targeting nuclear import and export of viral proteins (XPO1, XPO5, CSE1L, and TNPO3), or by interfering with the innate immune signaling pathway (Toll-like receptor signaling) (see Table S4A). Our findings complement and extend these earlier genome-wide RNAi knockdown studies, by identifying specific viral proteins (notably PA) which may interact with these essential host factors. Our findings together with published data also reveal a subset of host proteins that are capable of interacting with both the viral polymerase complex and additional virus proteins, such as NS1 (STAU1, TOP2A, and KPN) (13, 42, 52), NS2 (AIMP2 [JTV1]), M1 (STAU1), HA, and neuraminidase ([NA] RPS6KA3) (52). These inter-
actions suggest that some host factors may have multiple roles in the influenza virus life cycle.

The large number of putative binding partners identified in our analysis excludes a number of previously identified polymerase binding factors. This is because of our rigorous approach to excluding proteins that might nonspecifically copurify with the polymerase. Thus, we excluded all factors that were detected in the control lysate fraction in one or more experiments. The exclusion of these proteins from our analysis should not be interpreted as definitive evidence that they do not interact with the polymerase. Rather, it is simply a reflection of our conservative analytical approach. For example, IPO3 (TNPO2) and PARP-1, two of the 3P binders identified by Mayer et al. (41), were detected only in our set 2 sample and not in our set 1 sample and were therefore also excluded from further analysis. It should also be noted that proteins listed as associating only with PA or PA-PB1 may also bind to the 3P complex since host factor binding to the subunits may occur prior to complex formation.

Given the large number of polymerase binding factors that were identified in our analysis, it is not possible to discuss more than a few of them here. We have chosen to focus on those which reveal previously unappreciated cellular pathways that may be targeted by the influenza virus polymerase and which may provide insight into the virus life cycle. For a small subset of these host proteins, we went further and experimentally validated their ability to interact with the influenza virus polymerase (e.g., PTRF and Supt5H). Future studies will be required to fully explore and validate all of the pathways and interactions reported here. We have therefore provided a complete list of all identified factors together with their peptide
Our results suggest that PA has a range of functions in the influenza virus life cycle in addition to its previously described roles in the proteolytic degradation of viral and host proteins, the endonucleolytic cleavage of capped RNA primers, and transcript elongation (15, 16, 23, 51). Indeed, the large number of cellular proteins that were associated with PA alone was somewhat unexpected. Particularly interesting was the association of PA with over 30 mitochondrial proteins. An association of influenza virus proteins with mitochondrial factors has been reported before for PB1-F2, a regulator of influenza A virus-mediated apoptosis (8), and PB2, which interacts with IPS-1 in mitochondria (21), leading to the inhibition of interferon beta and antiviral signaling. To our knowledge, PA has not been found to associate with mitochondrial proteins before. The fact that PA associated with mitochondrial proteins that mediate outer (voltage-dependent anion channel protein 3 [VDAC3]) or inner membrane permeabilization (transmembrane transport proteins) (Fig. 4) suggests that PA may have a role in the regulation of apoptosis during influenza virus infection. The general role of VDACs in the induction of apoptosis is evident and has been extensively reviewed in the literature (50, 60). It is also conceivable that binding of these cellular proteins to PA could inhibit their function in a manner similar to the postulated antiapoptotic effects mediated by binding of NS1 to apoptosis-inducing proteins (39).

In addition, our study revealed the mitochondrial protein AIFM1 as one of the most readily detected host factor proteins in the PA fraction. This observation could be due to an overall higher cellular expression of AIFM1 and/or due to more specific binding of PA to AIFM1 than to other cellular factors that were identified. In healthy cells, AIFM1 is located on the inner membrane of mitochondria. However, upon apoptosis induction, nuclear translocation of AIFM1 occurs via a caspase-independent pathway. This pathway has recently been shown to be activated by influenza virus (H5N1), leading to mitochondrial dysfunction and cell death through the induction of an extracellular Ca2+ influx (62). However, the viral component involved in the activation of this caspase-independent pathway is unknown. Our results indicate a possible role for PA in this process.

We also examined the association of cellular factors with...
PA-PB1 and the 3P complex and discovered that the Pol II complex represents a major interaction network. Pol II itself has been previously reported to associate with the viral 3P complex. However, to our knowledge none of the Pol II-associated proteins have been shown to associate with the polymerase complex. HTat-SF1 has been described before only as an NP binding partner (45). It remains possible that Pol II is the main interactor with the viral polymerase and that associated factors such as SupSH and HTat-SF1 interact indirectly with the viral polymerase via Pol II. However, it is intriguing to speculate that some of these proteins may interact directly with the viral polymerase. For example, DNA damage-induced protein kinase DNA-PK (PRKD), an abundant factor present in the PA fraction, is important for DNA repair and the regulation of innate immune responses after viral infection through the phosphorylation of interferon regulatory factor 3 (IRF-3) (32). DNA-PK has also been implicated in regulating transcription by RNA polymerase II (53). In addition, HTat-SF1 may also be an important interacting protein since it has previously been described as an NP binding partner (45).

An important aspect of the virus life cycle, which is also related at least in part to interactions with Pol II, is virus-mediated shutoff of host protein synthesis. Our analysis revealed several host factor interactions which may contribute to this shutoff. For example, in addition to its interaction with members of the Pol II network (Fig. 8A), the viral polymerase was also associated with proteasomal proteins and E3 ubiquitin ligases (such as PJA2) (Fig. 7A and B). This supports the hypothesis that the viral polymerase may induce ubiquitination and degradation of Pol II (64). In addition, we found a novel association of PA with the aminoacyl-tRNA biosynthesis pathway, suggesting a previously unrecognized mechanism by which the virus may induce host-protein synthesis shutdown.

Our studies also revealed that several representatives of the caveolar-mediated endocytosis pathway, including members of the COPI coat complex (Fig. 3), are PA-binding partners. COPI components are important for HA trafficking (4), and depletion of some of these members (COPIG and ARCN1) has also been shown to block influenza virus infection at the entry step (5, 35). Moreover, epidermal growth factor receptor (EGFR), another PA-associated factor and member of this endocytic pathway, has been shown to promote uptake of influenza viruses (11). Interestingly, EGFR signaling and trafficking are also regulated by a number of other viruses, including hepatitis C virus (40), hepatitis E virus (7), human papillomavirus (55, 58), and herpes simplex virus type-1 (38), and this pathway may regulate postentry steps in the viral life cycle, including viral RNA synthesis, nuclear export of vRNPs, or release of virions (36). This finding underscores the notion that influenza virus may be susceptible to inhibition by small-molecule inhibitors of EGFR tyrosine kinase activity (36), possibly including antitumor drugs such as gefitinib (37).

In conclusion, the present analysis provides new insight into the cellular factors that associate with the influenza A virus RNA polymerase and suggests that the viral polymerase may significantly perturb cellular pathways involved in endocytosis, protein and RNA transport, and the regulation of apoptosis. Our data also reveal an unexpected interaction of polymerase proteins with mitochondrial proteins (including AIFM1) and with the RNA polymerase II machinery. These results suggest previously unappreciated roles for the influenza virus polymerase in regulating virus replication and pathogenesis and point the way to new antiviral strategies.

ACKNOWLEDGMENTS

We thank Shikha Chakraborty-Sett (University of Rochester) and John Heffron (FHCRC Proteomics) for excellent technical assistance and Marcus Korth and Lynn Law for critically reading the manuscript. We also thank Toru Takimoto (University of Rochester) for providing a titrated stock of influenza A/WSN/33 virus.

This project has been funded in part by federal funds from the Department of Health and Human Services, under contracts HHSN272200800060C (M.G.K.) and HHSN266200700008C (S.D.), the National Institute of Allergy and Infectious Diseases under U54 AI081680 (M.G.K.), and the National Center for Research Resources under P51RR000166 (M.G.K.).

REFERENCES


70. Vol. 85, 2011 INFLUENZA VIRUS POLYMERASE-ASSOCIATED HOST FACTORS 8581


